#United States #Berger Montague #Gaithersburg #Altimmune Inc. #Pemvidutide

Investor Alert: Altimmune Inc. Faces Class Action Lawsuit

A recent announcement from Berger Montague, a prominent national law firm, has investors of Altimmune Inc. (NASDAQ: ALT) on alert. The law firm has initiated a class action lawsuit against the biopharmaceutical company, which is based in Gaithersburg, Maryland, and specializes in therapies targeting obesity and liver disease, specifically MASH (metabolic dysfunction-associated steatohepatitis).

The lawsuit is aimed at investors who acquired shares of Altimmune between August 10, 2023, and June 25, 2025, referred to as the “Class Period.” In a significant turn of events, Altimmune's stock price plummeted by 53.2% in just one day following an announcement concerning the results of their IMPACT Phase 2b trial for Pemvidutide, a treatment intended to combat MASH.

On June 26, 2025, despite positive expectations raised by the management, the release of the trial results highlighted a failure to meet the primary statistical significance goal regarding fibrosis reduction, mainly due to an unexpectedly high placebo response rate. The company's stock, which had closed at $7.71 the previous day, fell to $3.61 following this announcement, sparking serious concerns among investors.

The law firm has set a deadline for investors interested in leading the class action to come forward no later than October 6, 2025. This action is crucial for those wishing to assert their rights concerning the substantial financial losses reportedly incurred due to the recent significant decline in stock value. Investors are encouraged to reach out for legal representation and to understand their rights regarding this situation.

To further assist affected investors, Berger Montague has provided contact details for inquiries. Andrew Abramowitz and Caitlin Adorni, attorneys at the firm, can be reached via their respective emails and phone numbers for detailed discussions on how to navigate this legal situation.

Background on Altimmune

Founded to develop innovative therapies for critical health issues, Altimmune has dedicated itself to addressing serious medical concerns like obesity and liver diseases. The company's focus on creating effective solutions has positioned it as a notable entity in the biopharmaceutical sector. However, the recent setback raises questions about its future prospects and reliability. Investors are now left to grapple with the implications of this legal action and the subsequent fallout from disappointing clinical trial results.

As the situation develops, the financial community will be closely monitoring Altimmune's response and recovery strategies, as well as ongoing communications from Berger Montague regarding this class action. The outcomes of the lawsuit could set precedents in securities litigation, potentially affecting investor relations and trust within the biopharmaceutical industry.

Ultimately, impacted investors must stay informed and proactive as they decide their next steps moving forward in light of this pressing legal challenge.